Drug intelligence / Profile preview

n-ethyl-n-nitrosourea

Development stage
Discontinued
Modality
Small Molecules
Administration
Laboratory Use (commonly Via Intraperitoneal Or Intravenous Injection In Animal Studies, Not Used In Clinical Human Therapy)
01

Overview

n-ethyl-n-nitrosourea (ENU) is a synthetic, highly potent mutagen and alkylating agent of the nitrosourea chemical class. It acts mainly by transferring its ethyl group to nucleobases (primarily thymine) in nucleic acids, leading to point mutations[5][9]. ENU is routinely used in genetic research, especially for mutagenesis studies in animal models—most notably in mice—because it induces new mutations at a much higher rate than spontaneous mutation or other chemical agents[5]. The compound is also recognized for its cytotoxicity and carcinogenic properties, causing cell death through direct DNA damage. Historically, it was studied as an experimental chemotherapy agent but is not used clinically due to toxicity. ENU is listed as a probable human carcinogen (IARC Group 2A) and poses a significant occupational and environmental health hazard[4][1].

Other names
n-nitroso-n-ethylureaethylnitrosourea1-ethyl-1-nitrosoureanitrosoethylureacarbamide n-ethyl-n-nitrosourea 1-ethyl-1-nitrosourea1-ethyl-1-nitrosourea-1-ethyl-1-nitroso
02

Targets

DNA

Beyond the preview

Go deeper on n-ethyl-n-nitrosourea.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on n-ethyl-n-nitrosourea.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call